Supernus Pharmaceuticals (SUPN) Debt to Equity: 2011-2025
Historic Debt to Equity for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Sep 2025 value amounting to $0.01.
- Supernus Pharmaceuticals' Debt to Equity fell 76.86% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.13, marking a year-over-year decrease of 34.28%. This contributed to the annual value of $0.05 for FY2024, which is 19.11% down from last year.
- Latest data reveals that Supernus Pharmaceuticals reported Debt to Equity of $0.01 as of Q3 2025, which was down 63.23% from $0.03 recorded in Q1 2025.
- Supernus Pharmaceuticals' 5-year Debt to Equity high stood at $0.52 for Q4 2021, and its period low was $0.01 during Q3 2025.
- Over the past 3 years, Supernus Pharmaceuticals' median Debt to Equity value was $0.05 (recorded in 2024), while the average stood at $0.05.
- Within the past 5 years, the most significant YoY rise in Supernus Pharmaceuticals' Debt to Equity was 1,518.63% (2022), while the steepest drop was 95.42% (2022).
- Over the past 5 years, Supernus Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.52 in 2021, then tumbled by 95.42% to $0.02 in 2022, then soared by 137.10% to $0.06 in 2023, then dropped by 19.11% to $0.05 in 2024, then tumbled by 76.86% to $0.01 in 2025.
- Its last three reported values are $0.01 in Q3 2025, $0.03 for Q1 2025, and $0.05 during Q4 2024.